Allogene Therapeutics, Inc. Common Stock
ALLO Real Time Price USDRecent trades of ALLO by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ALLO's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Inducible chimeric cytokine receptors Dec. 10, 2024
-
Patent Title: Methods of manufacturing allogeneic car t cells Dec. 10, 2024
-
Patent Title: Modified caspase-9 polypeptides and methods of use thereof Oct. 01, 2024
-
Patent Title: Constitutively active chimeric cytokine receptors Jul. 23, 2024
-
Patent Title: Bcma car-t cells with enhanced activities Jul. 16, 2024
-
Patent Title: Polynucleotides encoding rituximab-resistant chimeric antigen receptors Feb. 13, 2024
-
Patent Title: Chimeric cytokine receptors bearing a pd-1 ectodomain Oct. 17, 2023
-
Patent Title: Anti-talen antibodies and uses thereof Oct. 10, 2023
-
Patent Title: Antibodies against 4g7-derived chimeric antigen receptors Aug. 22, 2023
-
Patent Title: Dll3 targeting chimeric antigen receptors and binding agents Jun. 13, 2023
-
Patent Title: Modified caspase-9 polypeptides and methods of use thereof May. 10, 2022
-
Patent Title: Inhibitory chimeric antigen receptors Jul. 27, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of ALLO in WallStreetBets Daily Discussion
Recent insights relating to ALLO
Recent picks made for ALLO stock on CNBC
ETFs with the largest estimated holdings in ALLO
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ALLO Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.